United States · Platforms & data · MarketBeat
Evolus Eyes 2027 Sculpt Launch as Filler Portfolio Expands and Revenue Grows

Detailed summary
Evolus (NASDAQ:EOLS) executives said the company expects its expanding lineup of injectable aesthetics products to support growth as it prepares for the anticipated launch of Evolysse Sculpt in 2027. At a company event, CEO and President David Moatazedi said Evolus has diversified beyond its flagsh
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)




